
Opinion|Videos|August 23, 2024
Clinical Data Supporting Pneumococcal Vaccination
Key opinion leaders examine the pivotal clinical data that supported the FDA approvals of PCV15, PCV20, and PCV21, while also explaining the differences between polysaccharide and conjugate pneumococcal vaccines in terms of their induced immune responses and the durability of protection they offer.
Advertisement
Episodes in this series

What is the key data that led to the FDA-approvals of PCV15, PCV20, and PCV21?
How do the polysaccharide and conjugate pneumococcal vaccines differ in terms of immune response and durability?
- Can you discuss the potential long-term benefits of using conjugate vaccines over polysaccharide vaccines in adult populations and vice versa?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
2
Medetomidine: The Demon in the Illicit Fentanyl Supply
3
FDA Updates Boxed Warning for Cilta-Cel Following Reports of Immune Effector Cell–Associated Enterocolitis
4
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
5